FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Quart Barry D					<u>H</u>	2. Issuer Name and Ticker or Trading Symbol HERON THERAPEUTICS, INC. /DE/ [HRTX]								heck X	all applic	or		10% Ov	vner	
	Last) (First) (Middle) 4242 CAMPUS POINT COURT SUITE 200					3. Date of Earliest Transaction (Month/Day/Year) 06/21/2018								X	Cofficer (give title below) Chief Executive Officer					
(Street) SAN DIEGO CA 92121					_	4. If Amendment, Date of Original Filed (Month/Day/Year)									ndividual or Joint/Group Filing (Check Applicable E) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	•	(Zip)	au Davi	4:	- 6-				D:		4 au Da								
1. Title of Security (Instr. 3)			Date Ex (Month/Day/Year) if a		2A. Deemed Execution Date, f any Month/Day/Year)		3. Transaction Code (Instr.		4. Securitie	s Acquired (A) or of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price		Reported Transact (Instr. 3	tion(s)			(Instr. 4)	
Common Stock				04/30	04/30/2018				J ⁽¹⁾	V	1,607	A	\$13.21	175	69,	,600		D		
Common Stock				06/21	6/21/2018				M ⁽²⁾		50,000	A	\$9.0	5	119	9,600		D		
Common	Stock		06/21/201				018				50,000	D	\$39.0	39.05		69,600		D		
		-	Table II								oosed of, converti			y Oı	wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deen Executio if any (Month/D	n Date,	4. Transa Code (8)				6. Date Exercis Expiration Date (Month/Day/Ye		te	7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		De Se	Price of erivative ecurity istr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ully	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares							
Employee Stock Option (Right to	\$9.05	06/21/2018			M ⁽²⁾			50,000	(3)		12/12/2024	Common Stock	50,000		\$0.00	250,00	0	D		

Explanation of Responses:

- 1. Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2018.
- 2. The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017.
- 3. The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (12/12/2014).

Remarks:

/s/ Lisa <u>R. Peraza Attorney-in-</u> fact for Barry D. Quart

06/22/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.